Sun Pharma: USFDA Scrutinizes Mohali plant in Punjab
New Delhi: Drug major Sun Pharmaceutical Industries said the US health regulator is conducting an inspection of its Mohali facility in Punjab. The inspection by the United States Food and Drug Administration (USFDA) started on September 10, 2018, and is ongoing, Sun Pharma said in a filing to BSE.
The company, however, did not provide any further details of the inspection.
In 2017, the US regulator had proposed to lift import alert on a Mohali-based plant.
The USFDA, in September 2013, had issued an import alert on drugs produced at the then Ranbaxy's Mohali plant for violation of current good manufacturing practices.
Last week, the USFDA had issued Form 483 with six observations after an inspection of the company's Halol facility in Gujarat.
The US regulator had conducted a pre-approval inspection (PAI) of the Halol plant in August, Sun Pharma had said in a regulatory filing.
The company, however, did not provide any further details of the inspection.
In 2017, the US regulator had proposed to lift import alert on a Mohali-based plant.
The USFDA, in September 2013, had issued an import alert on drugs produced at the then Ranbaxy's Mohali plant for violation of current good manufacturing practices.
Last week, the USFDA had issued Form 483 with six observations after an inspection of the company's Halol facility in Gujarat.
The US regulator had conducted a pre-approval inspection (PAI) of the Halol plant in August, Sun Pharma had said in a regulatory filing.
Next Story
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd